Many medicines for children – especially inexpensive ones whose patents have expired – are not available on the Swiss market. Some new products are not launched because the approval requirements are considered too high and the sales price too low for the small market. At the meeting of the parliamentary group on pediatric and adolescent medicine, a solution was proposed that can be implemented at ordinance level, provided there is the political will to do so. Many factors lead to a shortage of pediatric medicines, only some of which a small country like Switzerland can influence itself. The Expert Group on Pediatrics and Adolescent Medicine has commissioned the Bernese doctor and lawyer Andreas Wildi (WalderWyss) to draw up a proposal for a solution to improve the supply of expired paediatric medicinal products that can be implemented at ordinance level. At the meeting of the parliamentary group, National Councillor and Co-President Benjamin Roduit (center VS) gave an introduction. “If you ask the price watchdog, the prices of patent-expired medicines are too high; if you ask the industry, they are too low,” explained Roduit. Marc Sidler, President of Pediatrics Switzerland, pointed out how many medicines are missing in practice today and the work involved for paediatricians. Andreas Wildi presented his proposal. This provides for pediatricians to draw up a list of the medicines they require for outpatient and inpatient use. Medicinal products that are on the list but are not available in Switzerland or are (no longer) authorized are to be legally procured for a limited period of time by amending the ordinances. The focus is on partial revisions of the Ordinance on the Compulsory Stockpiling of Medicinal Products and the EAER Ordinance on the Compulsory Stockpiling of Medicinal Products, the Medicinal Products Licensing Ordinance (MPLO) and the Ordinance on Health Insurance (KVV). Pharmacist Franz von Heeren (Mepha / Teva) highlighted the problem that sales in the area of off-patent pediatric drugs are so low that they often do not cover the costs of maintaining a marketing authorization. Pharmacist Nadine Broder, Head of the Therapeutic Products Unit, highlighted the possibilities and limitations of the Federal Office for National Economic Supply FONES. Councillor of States and Co-President Flavia Wasserfallen (SP BE) moderated the subsequent question and answer session with aplomb. Some representatives of the authorities defended their position that national approval is always necessary to ensure patient safety and the quality of medicines. It was countered that the proposed solution was safer than the costly and complicated individual import that is legally possible today. Other representatives of the authorities were open to a political mandate to improve security of supply.